1-2 of 2
Nick Pirooz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Vania Hungria, Pawel Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, Phoebe Joy Ho, Roman Hajek, Kihyun Kim, Sebastian Grosicki, Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Gracia Aparecida Martinez, Anna Maria Sureda Balarí, Irwindeep Sandhu, Claudio Cerchione, Peter Ganly, Meletios Dimopoulos, Chengcheng Fu, Mamta Garg, Al-Ola Abdallah, Moshe E Gatt, Albert Oriol, Michele Cavo, Robert Rifkin, Tomoaki Fujisaki, Michał Mielnik, Nick Pirooz, Joe Lee, Astrid McKeown, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy-Ghanta, Maria Victoria Mateos
Journal: Blood
Blood (2024) 144 (Supplement 1): 772.
https://doi.org/10.1182/blood-2024-200336
Published: 2024
Journal Articles

A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity.

Craig B. Reeder, MD, Donna E. Reece, Vishal Kukreti, MD, FRCPC, Joseph R. Mikhael, MD, Christine Chen, MD, Suzanne Trudel, MD, Kristina Laumann, Joseph Hentz, Nick Pirooz, Jg Piza, MD, Victor J Jimenez Zepeda, Rafael Fonseca, P. Leif Bergsagel, Jose Leis, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, A. Keith Stewart, MBChB
Journal: Blood
Blood (2009) 114 (22): 616.
https://doi.org/10.1182/blood.V114.22.616.616
Published: 2009